FDA Nod for J&J Autoimmune Drug is First of Potentially Many for the Projected Blockbuster Product
Frank Vinluan , 2025-05-01 19:50:00 A Johnson & Johnson autoimmune disease medicine that’s a relative latecomer in its drug class can now compete in its first FDA-approved indication with a label that covers a broader patient population than products already available from Argenx and UCB. The FDA has approved the J&J drug, known in development…